The cytotoxic anti-cancer drugs cisplatin, paclitaxel, doxorubicin, 5-fluorouracil (5-FU), as
well as targeted drugs including imatinib, erlotinib, and nivolumab, play key roles in clinical …

The nuclear transport proteins, importins and exportins (karyopherin-β proteins), may play
an important role in cancer by transporting key mediators of oncogenesis across the nuclear …

Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces
apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the …

Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which
blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor …

Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor
prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first …

Novel therapies are needed for patients with relapsed or refractory multiple myeloma (MM).
We conducted a multicenter, phase 1 study in advanced hematological malignancies to …

Treating cancer through inhibition of nuclear export is one of the best examples of basic
research translation into clinical application. Nuclear export factor chromosomal region …

Purpose To characterize the toxicity, pharmacokinetics, and pharmacodynamics of
selinexor, a selective inhibitor of nuclear export, when combined with fludarabine and …

Abstract Exportin-1 (XPO1) controls the nucleo-cytoplasmic trafficking of several key growth
regulatory and tumor suppressor proteins. Nuclear export blockade through XPO1 inhibition …

Introduction: Despite unprecedented advances in the treatment of multiple myeloma (MM),
almost all patients develop a disease that is resistant to the five most commonly used and …